ClinicalTrials.gg
TerminatedNCT01467505Updated Jun 18, 2015Results posted

An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

A Phase 2 interventional study of Telaprevir and Ribavirin in Hepatitis C, sponsored by Vertex Pharmaceuticals Incorporated. Terminated at 22 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-06-18.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated early by the sponsor on 13 January 2014 due to a decision to modify the drug development plan.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
61
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing telaprevir in Hepatitis C — none open to participants now, none under way, none of them phase 3. telaprevir · Hepatitis C.

Enrollment
14th of 39
61 · median 30
Started
2012
with 11 others
Phase 2
8 of 39
none open now
Registered
21st of 39
by date
Lead sponsor
12 of 39
Vertex Pharmaceuticals Incorporated

Among the 39 studies testing telaprevir in Hepatitis C, this one is the 14th largest by enrollment, is one of 12 that started in 2012, is one of 8 in phase 2, and was the 21st registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 39 studies testing telaprevir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About telaprevir

telaprevir: first FDA approval 2011 (INCIVEK), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing telaprevir in Hepatitis C as a file.
02

Study summary

To assess efficacy of telaprevir, pegylated interferon alfa-2a (Peg-IFN-alfa-2a), and ribavirin (RBV) for hepatitis C virus (HCV) in a 48-week total treatment duration regimen following liver transplantation.

03

Conditions studied

  • Hepatitis C

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants between the ages of 18 and 65 years
  • History of orthotopic liver transplantation less than 10 years before the Screening visit but no sooner than 6 months before Day 1
  • Taking a stable regimen based on either tacrolimus or cyclosporine without substantial dose changes over the past 3 months
  • Naive to pegylated interferon/ribavirin treatment or experienced with pegylated interferon/ribavirin prior to transplantation with relapse, partial, or null response

Exclusion criteria

Exclusion Criteria:

  • Documented cirrhosis after liver transplantation
  • Ascites or hepatic encephalopathy within 6 months before Screening
  • Retransplantation for recurrent
  • Treatment for hepatitis C post liver transplantation
  • History within the past 3 months of: rejection within 3 months or greater than (>) 1 rejection within 12 months
  • Current treatment with sirolimus or methylprednisolone. Low dose prednisone use (\<5 milligram per day) is permitted
  • History within 3 months of any bacterial infection requiring >1 week of intravenous antibiotics, cytomegalovirus viremia or cytomegalovirus infection with end-organ involvement, fungal disease (except cutaneous and mild oral thrush)
  • History of post transplant lymphoproliferative disease
  • Acceptable laboratory values at Screening as specified in the protocol
  • Positive for 1/2 (HIV1/2) enzyme immunoassay (EIA) antibody screen or deoxyribonucleic acid (DNA) or Hepatitis B surface antigen
  • History of hepatocellular carcinoma with high risk of recurrence
  • Any other cause of liver disease deemed by the investigator in addition to hepatitis C
  • -mediated disease
  • History of acute pancreatitis within 5 years before the Screening visit
  • Prior treatment with an hepatitis C virus (HCV) protease inhibitor
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    T/PR + Immunosuppressant Regimen (Tacrolimus)

    Participants who were receiving tacrolimus (TAC) based immunosuppressant regimen at baseline, received telaprevir (T) 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (\<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (\>=) 75 kg, for 48 weeks. Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.

    Drug: Telaprevir · Drug: Ribavirin · Drug: Pegylated Interferon Alfa-2a · Drug: Immunosuppressant Regimen

  • Experimental
    T/PR + Immunosuppressant Regimen (Cyclosporine)

    Participants who were receiving cyclosporine (CsA) based immunosuppressant regimen at baseline, received telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 48 weeks. Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.

    Drug: Telaprevir · Drug: Ribavirin · Drug: Pegylated Interferon Alfa-2a · Drug: Immunosuppressant Regimen

Interventions

  • Tablet

    Also known as: VX-950

  • Tablet

    Also known as: Copegus®, RBV

  • Subcutaneous Injection

    Also known as: Pegasys®, Peg-IFN-alfa-2a

  • DrugImmunosuppressant Regimen

    Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice. Immunosuppressant regimen were not considered study drugs.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)

    SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (\<lower limit of quantification) at 12 weeks after last planned dose of study treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL).

    Time frame: 12 weeks after last planned dose of study drug (up to Week 60)

Secondary outcomes

  1. Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)

    SVR24 was defined as an undetectable HCV RNA Levels at 24 weeks after last planned dose of study treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL.

    Time frame: 24 weeks after last planned dose of study drug (up to Week 72)

  2. Percentage of Participants With Rapid Viral Response (RVR)

    The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. RVR was defined as undetectable HCV RNA 4 weeks after the start of study treatment.

    Time frame: Week 4

  3. Percentage of Participants With Extended Rapid Viral Response (eRVR)

    The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. eRVR was defined as undetectable HCV RNA at both 4 weeks and 12 weeks after the start of study treatment.

    Time frame: Week 4 and Week 12

  4. Percentage of Participants With On-Treatment Virologic Failure

    On-treatment virologic failure was defined as subjects who met futility or who completed the assigned treatment duration and had detectable HCV RNA at planned end of treatment (up to 48 weeks). Data for this outcome was not planned to be reported by prior response.

    Time frame: Baseline up to Week 48

  5. Percentage of Participants With Viral Relapse

    Time frame: 48 weeks

  6. Pharmacokinetics of Telaprevir, Peg-IFN, RBV , and Selected Immunosuppressant Medications (Tacrolimus and Cyclosporine)

    Time frame: 48 weeks

  7. Percentage of Participants Requiring Dose Titration of Immunosuppressant Medications

    Time frame: 48 weeks

  8. Percentage of Participants With Biopsy Confirmed and Treated Rejection

    Time frame: 48 weeks

  9. Percentage of Participants With Histological Evidence of Stabilization or Improvement in Inflammation Grade or Fibrosis Stage

    Time frame: 48 weeks

  10. Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region

    Time frame: 48 weeks

  11. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Any adverse change from the participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. "Study drug" includes all investigational agents (including placebo, if applicable) administered during the course of the study.

    Time frame: Baseline up to Week 52

Other outcomes

  1. Percentage of Participants With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4)

    Time frame: 4 weeks after last planned dose of study drug (up to Week 52)

07

Results

Posted Jun 18, 2015
Limitations and caveats
It was decided by Sponsor on 13 January 2014 to terminate the study early at the primary efficacy endpoint (SVR12) as part of a decision to modify the drug development plan. Eligible participants completed virologic follow-up after termination.

Participant flow

Study included Treatment-Naïve (no prior hepatitis C virus \[HCV\] therapy); Prior Relapser (prior treatment with pegylated interferon alfa/ribavirin \[Peg-IFN/RBV\] and experienced viral relapse); Prior Null/Partial Responder (prior treatment with Peg-IFN/RBV and had null/partial response); Uncategorized (could not tolerate treatment) participants.

Participant flow — Overall Study
MilestoneT/PR + Immunosuppressant Regimen (Tacrolimus)T/PR + Immunosuppressant Regimen (Cyclosporine)
Started5110
Completed187
Not completed333
Withdrew: Adverse event10
Withdrew: Withdrawal by subject40
Withdrew: Study terminated by sponsor283

Outcome measures

PrimaryPercentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)

SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (\<lower limit of quantification) at 12 weeks after last planned dose of study treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL).

Time frame:
12 weeks after last planned dose of study drug (up to Week 60)
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)
percentage of participantsT/PR + Immunosuppressant Regimen (Tacrolimus)T/PR + Immunosuppressant Regimen (Cyclosporine)
Naive (n= 16, 2)75.050.0
Prior Relapser (n= 10, 2)60.0100.0
Prior Null Responder (n=16, 4)37.550.0
Prior Partial Responder (n= 3, 1)66.7100.0
Uncategorized (n= 6, 1)50.0100.0
Total (n= 51, 10)56.970.0
SecondaryPercentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)

SVR24 was defined as an undetectable HCV RNA Levels at 24 weeks after last planned dose of study treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL.

Time frame:
24 weeks after last planned dose of study drug (up to Week 72)
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)
percentage of participantsT/PR + Immunosuppressant Regimen (Tacrolimus)T/PR + Immunosuppressant Regimen (Cyclosporine)
Naive (n= 5,1)60.00
Prior Relapser (n= 4,1)25.00
Prior Null Responder (n=10, 4)20.050.0
Prior Partial Responder (n= 0, 1)0100.0
Uncategorized (n= 5, 0)20.00
Total (n= 24, 7)29.242.9
SecondaryPercentage of Participants With Rapid Viral Response (RVR)

The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. RVR was defined as undetectable HCV RNA 4 weeks after the start of study treatment.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Rapid Viral Response (RVR)
percentage of participantsT/PR + Immunosuppressant Regimen (Tacrolimus)T/PR + Immunosuppressant Regimen (Cyclosporine)
Naive (n= 16, 2)68.80
Prior Relapser (n= 10, 2)50.050.0
Prior Null Responder (n=16, 4)43.825.0
Prior Partial Responder (n= 3, 1)66.7100.0
Uncategorized (n= 6, 1)33.30
Total (n= 51, 10)52.930.0
SecondaryPercentage of Participants With Extended Rapid Viral Response (eRVR)

The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. eRVR was defined as undetectable HCV RNA at both 4 weeks and 12 weeks after the start of study treatment.

Time frame:
Week 4 and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Extended Rapid Viral Response (eRVR)
percentage of participantsT/PR + Immunosuppressant Regimen (Tacrolimus)T/PR + Immunosuppressant Regimen (Cyclosporine)
Naive (n= 16, 2)68.80
Prior Relapser (n= 10, 2)50.050.0
Prior Null Responder (n=16, 4)37.525.0
Prior Partial Responder (n= 3, 1)66.7100.0
Uncategorized (n= 6, 1)33.30
Total (n= 51, 10)51.030.0
SecondaryPercentage of Participants With On-Treatment Virologic Failure

On-treatment virologic failure was defined as subjects who met futility or who completed the assigned treatment duration and had detectable HCV RNA at planned end of treatment (up to 48 weeks). Data for this outcome was not planned to be reported by prior response.

Time frame:
Baseline up to Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With On-Treatment Virologic Failure
percentage of participantsT/PR + Immunosuppressant Regimen (Tacrolimus)T/PR + Immunosuppressant Regimen (Cyclosporine)
Percentage of Participants With On-Treatment Virologic Failure00
SecondaryPercentage of Participants With Viral Relapse
Time frame:
48 weeks

No measurements were reported for this outcome.

SecondaryPharmacokinetics of Telaprevir, Peg-IFN, RBV , and Selected Immunosuppressant Medications (Tacrolimus and Cyclosporine)
Time frame:
48 weeks

No measurements were reported for this outcome.

SecondaryPercentage of Participants Requiring Dose Titration of Immunosuppressant Medications
Time frame:
48 weeks

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Biopsy Confirmed and Treated Rejection
Time frame:
48 weeks

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Histological Evidence of Stabilization or Improvement in Inflammation Grade or Fibrosis Stage
Time frame:
48 weeks

No measurements were reported for this outcome.

SecondaryNumber of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region
Time frame:
48 weeks

No measurements were reported for this outcome.

SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Any adverse change from the participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. "Study drug" includes all investigational agents (including placebo, if applicable) administered during the course of the study.

Time frame:
Baseline up to Week 52
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsT/PR + Immunosuppressant Regimen (Tacrolimus)T/PR + Immunosuppressant Regimen (Cyclosporine)
AEs5110
SAEs113
Other pre-specifiedPercentage of Participants With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4)
Time frame:
4 weeks after last planned dose of study drug (up to Week 52)

No measurements were reported for this outcome.

Adverse events

Collected over Baseline up to Week 52. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T/PR + Immunosuppressant Regimen (Tacrolimus)—11/51 (21.6%)51/51 (100%)
T/PR + Immunosuppressant Regimen (Cyclosporine)—3/10 (30%)10/10 (100%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventT/PR + Immunosuppressant Regimen (Tacrolimus)T/PR + Immunosuppressant Regimen (Cyclosporine)
Herpes zosterInfections and infestations0/511/10
PneumoniaInfections and infestations0/511/10
Coronary artery diseaseCardiac disorders0/511/10
Pleural effusionRespiratory, thoracic and mediastinal disorders0/511/10
NauseaGastrointestinal disorders4/510/10
VomitingGastrointestinal disorders4/510/10
AnaemiaBlood and lymphatic system disorders2/510/10
Impaired gastric emptyingGastrointestinal disorders1/510/10
ProctalgiaGastrointestinal disorders1/510/10
PainGeneral disorders1/510/10
Most frequent other events
Showing 10 of 234
Most frequent other events
EventT/PR + Immunosuppressant Regimen (Tacrolimus)T/PR + Immunosuppressant Regimen (Cyclosporine)
FatigueGeneral disorders36/517/10
RashSkin and subcutaneous tissue disorders18/517/10
AnaemiaBlood and lymphatic system disorders28/517/10
HeadacheNervous system disorders26/516/10
NauseaGastrointestinal disorders29/514/10
DiarrhoeaGastrointestinal disorders24/513/10
PruritusSkin and subcutaneous tissue disorders21/512/10
Anal pruritusGastrointestinal disorders7/514/10
Anorectal discomfortGastrointestinal disorders14/513/10
Influenza like illnessGeneral disorders6/513/10

Baseline characteristics

Full analysis set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)T/PR + Immunosuppressant Regimen (Tacrolimus)T/PR + Immunosuppressant Regimen (Cyclosporine)Total
Mean56.8 ± 4.0859.5 ± 2.9557.3 ± 4.02
Sex: Female, Male
Sex: Female, Male(Participants)T/PR + Immunosuppressant Regimen (Tacrolimus)T/PR + Immunosuppressant Regimen (Cyclosporine)Total
Female12012
Male391049
08

Study locations

22 sites
  • Alabama
    Birmingham, Alabama, United States
  • Arizona
    Phoenix, Arizona, United States
  • California
    Los Angeles, California, United States
  • Colorado
    Denver, Colorado, United States
  • Florida
    Bradenton, Florida, United States
  • Florida
    Miami, Florida, United States
  • Illinios
    Evanston, Illinois, United States
  • Indiana
    Indianapolis, Indiana, United States
  • Massachusetts
    Burlington, Massachusetts, United States
  • Michigan
    Ann Arbor, Michigan, United States
  • Michigan
    Detroit, Michigan, United States
  • Missouri
    St Louis, Missouri, United States
  • Nebraska
    Omaha, Nebraska, United States
  • New York
    New York, New York, United States
  • New York
    Rochester, New York, United States
  • North Carolina
    Charlotte, North Carolina, United States
  • Ohio
    Cleveland, Ohio, United States
  • Pennsylvania
    Philadelphia, Pennsylvania, United States
  • Texas
    Dallas, Texas, United States
  • Texas
    Houston, Texas, United States
  • Calgary, Alberta, Canada
  • Vancouver, British Columbia, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2011
First posted
Nov 8, 2011
Start
Feb 2012
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results first posted
Jun 18, 2015
Last update
Jun 18, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01467505
Responsible party
Sponsor
First posted
Nov 8, 2011
Start date
Feb 2012
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
Jun 18, 2015
Last update
Jun 18, 2015

Study contacts

Medical Monitor
study director · Vertex Pharmaceuticals Incorporated

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telaprevir · Ribavirin · Peginterferon alfa-2a

Start the discussion